Taking the breast cancer drug anastrozole for five years reduced the chances of post-menopausal women at high risk of breast cancer developing the disease by 53 per cent compared with women who took a placebo, according to a study presented at SABCS 2103.

The results of the IBIS II trial could offer a new option for preventing breast cancer in high risk post-menopausal women which is more effective than tamoxifen and has fewer side-effects.

Read more here